R&D | November 07, 2025
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Subscribe To Our Newsletter & Stay Updated
